Over the course of our more than 135 years in business, ´óÐãÊÓƵ has proven time and again that we can adeptly navigate through periods of uncertainty. As you can see in our first-quarter 2025 results, our diversified business model allowed us to deliver strong, sustainable growth and reaffirm our full-year guidance – even in a rapidly evolving environment.
Worldwide sales for the quarter were $10.4 billion, a 6.9% increase on an organic basis1 (4.0% reported). Adjusted diluted earnings per share (EPS) came in at $1.09, beating Street consensus of $1.07 and above the midpoint of our guidance (GAAP diluted EPS was $0.76).
Underscoring the strength of our diversified business model, first-quarter sales growth spanned multiple key business units. Medical Devices sales increased almost 13% on an organic basis (9.9% reported), marking yet another quarter of double-digit growth. That performance was led by a nearly 20% organic increase in Diabetes Care sales (16.5% reported), with particularly strong U.S. growth of 27%. Medical Devices results were also boosted by strong growth in Structural Heart, Heart Failure and Electrophysiology.
Established Pharmaceuticals sales grew about 8% on an organic basis (2.7% reported), with balanced performance across multiple markets and products. Nutrition sales increased almost 7% on an organic basis (3.8% reported), led by nearly 9% organic growth in Adult Nutrition (4.4% reported), which was driven by strong sales of Ensure®, ´óÐãÊÓƵ's market-leading complete and balanced nutrition brand, and Glucerna®, ´óÐãÊÓƵ's market-leading brand of products designed to meet the nutritional requirements for people with diabetes.
We also continue to strengthen our new product pipeline and broaden the impact of our life-saving technologies. Milestones from the first quarter include:
For full financial data and reconciliation of non-GAAP measures, you can read ´óÐãÊÓƵ’s full .
For more information, view a summary of ´óÐãÊÓƵ’s earnings highlights and download it here.
References
1 Organic sales growth excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business.
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. ´óÐãÊÓƵ cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect ´óÐãÊÓƵ's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. ´óÐãÊÓƵ undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Important safety information
TRICLIPâ„¢ G4 SYSTEM
Rx Only
INDICATIONS
The TriClipâ„¢ G4 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.
CONTRAINDICATIONS
The TriClip G4 System is contraindicated in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve. POTENTIAL
ADVERSE EVENTS
The following events have been identified as possible complications of the TriClipâ„¢ G4 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, and unstable / stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy, Transesophageal echocardiogram (TEE) and Transthoracic echocardiogram (TTE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea / vomiting; Pain; Pericardial effusion; Stroke / Cerebrovascular accident (CVA) and Transient Ischemic Attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction / failure / atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single Leaflet Device Attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, Persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thromboembolism (including deep vein thrombosis, pulmonary embolism). CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at https://www.eifu.abbott/ for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Share